Skip to search boxSkip to navigationSkip to main content

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

  • Oliver Ottmann(corresponding author)
    ,
  • Giuseppe Saglio
    ,
  • Jane F. Apperley
    ,
  • Christopher Arthur
    ,
  • Eduardo Bullorsky
    ,
  • Aude Charbonnier
*Corresponding author for this work
  • Cardiff University
    ,
  • University of Turin
    ,
  • Imperial College London
    ,
  • Royal North Shore Hospital
    ,
  • Hospital Británico de Buenos Aires
    ,
  • Institut Paoli Calmettes
Scholary Output:
Contribution to journal
Letter
 Peer-review

Publication Information

Output type

Scholary Output:
Contribution to journal
Letter
 Peer-review

Original language

English (US)

Article number

88

Journal (Volume, Issue Number)

Blood Cancer Journal (Volume 8, Issue 9)

Publication milestones

  • Published - 09/01/2018

Publication status

Published - 09/01/2018

ISSN

2044-5385

Publication IDs

  • Scopus: 85052925537
  • PubMed: 30190469
  • ORCID: /0000-0002-8636-1071/work/68888047

Access to documents

Publication metrics

Metrics

SciVal
FWCI
1.46
SciVal
Author count
13
SciVal
citations
5
SciVal
Paper percentile
67
Fractional count
1
Fractional count
0.08
Fractional count
12
Fractional count
0.92
Fractional count
1
Fractional count
1
Scopus
citations
24, opens in new tab

PlumX, opens in new tab

Captures
24
Usage
91
Citation count
22

Funding Details

O.O. has acted as a consultant, advisor, or speaker for ARIAD, Bristol-Myers Squibb, Celgene, Fusion Pharma, Novartis, Pfizer, Roche, and SUN Pharma. G.S. has acted as a consultant and a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. J.F.A. is an NIHR Senior Investigator and acknowledges the support of the Imperial College NIHR Biomedical Research Centre and has acted as a consultant, speaker, and advisor for ARIAD, Bristol-Myers Squibb, Incyte, Novartis, Pfizer, and SUN Pharma. C.A. has served on advisory boards and acted as a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. E.B. has no disclosures to declare. A.C. has served on advisory boards and has acted as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. J.F.D. has no disclosures to declare. H.K. has served on advisory boards for ARIAD, Bristol-Myers Squibb, Novartis, and Pfizer. H.J.K. has no disclosures to declare. D.-W.K. has received research funding from and served on an advisory committee for Bristol-Myers Squibb. D.H. and L.S. are employees of Bristol-Myers Squibb. J.C. has served as a consultant to and received research funding from ARIAD, Bristol-Myers Squibb, Novartis, Pfizer, and Teva. The authors would like to thank all participating study sites for this Bristol-Myers Squibb–sponsored analysis. Professional medical writing and editorial assistance were provided by Kelly M. Fahrbach, PhD, of StemScientific, an Ashfield Company, part of UDG Healthcare plc, funded by Bristol-Myers Squibb. The authors did not receive financial compensation from Bristol-Myers Squibb for authoring this manuscript.
FundersFunding numbers
BMS
-
Novartis
-
Pfizer
-
NIHR
-
BRC
-